EP1421063A1 - Ligands de bisulfure et de thiosulfonate, et bibliotheques les comprenant - Google Patents

Ligands de bisulfure et de thiosulfonate, et bibliotheques les comprenant

Info

Publication number
EP1421063A1
EP1421063A1 EP02746365A EP02746365A EP1421063A1 EP 1421063 A1 EP1421063 A1 EP 1421063A1 EP 02746365 A EP02746365 A EP 02746365A EP 02746365 A EP02746365 A EP 02746365A EP 1421063 A1 EP1421063 A1 EP 1421063A1
Authority
EP
European Patent Office
Prior art keywords
aryl
heteroaryl
aliphatic
heteroaliphatic
library
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02746365A
Other languages
German (de)
English (en)
Inventor
Andrew C. Braisted
Daniel A. Erlanson
Jeffrey W. Jacobs
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viracta Therapeutics Inc
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/990,421 external-priority patent/US6919178B2/en
Priority claimed from US10/121,216 external-priority patent/US6998233B2/en
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Publication of EP1421063A1 publication Critical patent/EP1421063A1/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C40—COMBINATORIAL TECHNOLOGY
    • C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B40/00—Libraries per se, e.g. arrays, mixtures
    • C40B40/04—Libraries containing only organic compounds

Definitions

  • the drug discovery process begins with the screening of a large number of compounds to identify modest affinity leads (K d ⁇ 1 to 10 ⁇ M).
  • An important tool in this process is the use of combinatorial libraries.
  • combinatorial methods for the generation of small molecule libraries and subsequent screening en masse have become important technologies for the identification of small molecule ligands to biological macromolecules (see, for example, Thompson et al. Chem. Rev. 1996, 96, 555-600; Balkenhohel et al. Angew. Chem. Int. Ed. Engl 1996, 35, 2288-2337; Dolle, R.E. Mol.
  • the disulfide-tethered fragments can then be identified by a variety of methods, including mass spectrometry (MS), and their affinity improved by traditional approaches upon removal of the disulfide tether. See also PCT Publication No. WO 00/00823, published on January 6, 2000 and U.S. Patent No. 6,335,155
  • Figure 1 schematically illustrates one embodiment of the tethering method.
  • Figure 2A depicts the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates with little or no binding affinity for TS.
  • Figure 2B depicts the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates where one of the ligand candidates possesses an inherent binding affinity to the enzyme.
  • Figure 3 depicts three experiments where TS is reacted with the same library pool containing the selected N-tosyl D-proline compound in the presence of increasing concentration of the reducing agent, 2-mercaptoethanol.
  • Figure 4 depicts schematically how tethering is utilized to identify a binding determinant.
  • Figure 5 depicts schematically a method where two separate tethering experiments are used to identify binding determinants that are subsequently linked together to form a conjugate molecule that binds to the target protein.
  • Figure 6 illustrates one embodiment of the tethering method using extenders.
  • the present invention expands upon the general tethering approach described above and provides novel compounds and libraries of compounds for use in this approach.
  • novel compounds and libraries described herein provide powerful tools for the development of drug leads, and are useful for the identification of fragments that bind weakly, or with moderate binding affinity, to a biological target site of interest.
  • the compounds of the invention include compounds and libraries of the general formula (I) as further defined below:
  • A is -S(CH 2 ) P R A1 or-SCO ⁇ R ⁇ , wherein p is 1-5, R A1 is -NR A3 R M ; OR ⁇ ; SR ⁇ ; -NHCOR A3 ; -NHCONR A3 R A4 ; -NR A3 R A4 R A5+ X _ , wherein X is a halogen; -COOR A3 ; CONR A3 R A4 ; -SOsR ⁇ ; -OPO 3 R A3 ; -SO 2 R A3 ; and wherein R ⁇ is an aliphatic, heteroaliphatic, aryl, or heteroaryl moiety, and each occurrence of R ⁇ , R A4 , and R A5 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl or heteroaryl moiety; n is 0-5;
  • L is a moiety having one of the structures:
  • each occurrence of R 1 and R 2 is independently hydrogen, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, or wherein R 1 and R 2 taken together are a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety; whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • r is 1 or 2; and t is 0, 1 or 2.
  • compounds and libraries of special interest include
  • R ⁇ is an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, (alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
  • R ⁇ is methyl or phenyl.
  • R 1 and R 2 is "O ⁇ f' m or R R 4 , or wherein R 1 and R 2 taken together
  • R 1 and R 2 are each independently hydrogen or a cycloaliphatic, heterocycloaliphatic, aryl or heteroaryl moiety optionally substituted with a substituted heteroaryl moiety.
  • compounds and libraries of special interest include those compounds and libraries as generally described above, in which the substituted heteroaryl moiety has one of the structures:
  • R 9 is -COO(R 10 ), -CO(R 10 ), -CO(NR 10 R ⁇ ), -N ⁇ -NR ⁇ COR 11 , -OR 10 , or -SR 10 , wherein each occurrence of R 10 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • each library member has a mass that differs from another library member by at least 5 atomic mass units;
  • embodiments exclude compounds where L is , and R is any one of the following
  • R D , R E R 5 or R 6 is -SO 2 -(alkyl) or -SO 2 -
  • O i ⁇ ⁇ ⁇ R A1 embodiments exclude compounds having the structure: H 9 where
  • R A1 is NR A3 R A4 or NR A3 R A4 R A5 ⁇ -, wherein each occurrence of R 3 , R A4 and R ⁇ is hydrogen or a protecting group, and X is a halogen; and R 1 is one of the following:
  • compounds of particular interest include, among others, those which share the attributes of one or more of the foregoing subclasses. Some of those subclasses are illustrated by the following sorts of compounds:
  • R ⁇ V which :L is o and R 1 has one of the following structures:
  • R D and R G are each independently hydrogen, a protecting group, -(CR 7 R 8 ) q S(O) 2 R 5 ; or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or - (heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or
  • R D is hydrogen, a protecting group, -(CR 7 R 8 ) q S(O) 2 R 5 ; or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each
  • R D is a protecting group, - (CR 7 R 8 ) q S(O) 2 R 5 ' or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the
  • Rl ⁇ V above in which L is ° , and R 1 has one of the following structures:
  • R D is hydrogen, a protecting group, - (CR 7 R 8 ) q S(O) 2 R 5 ' or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, - (aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, and wherein each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryl, - (heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each
  • R 1 has one of the following structures: D
  • each occurrence of R 2 , R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • each occurrence of R 5 and R 6 is independently hydrogen, a protecting group or an aliphatic, heteroaliphatic, aryl, heteroaryl, - (aliphatic)aryl, -(aliphatic)heteroaryl, -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl moiety, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • R 9 is COOH or is CO(NR 10 R n ), wherein each occurrence of R 10 and R 11 is independently hydrogen, a protecting group, or an aliphatic, heteroaliphatic, aryl, heteroaryl, -(aliphatic)aryl, -(aliphatic)heteroaryL -(heteroaliphatic)aryl, or -(heteroaliphatic)heteroaryl, whereby each of the foregoing aliphatic and heteroaliphatic moieties is substituted or unsubstituted, cyclic or acyclic, linear or branched and each of the foregoing cycloalipahtic, heterocycloaliphatic, aryl or heteroaryl moieties is independently substituted or unsubstituted.
  • Some of the foregoing compounds can exist in various isomeric forms, e.g., stereoisomers and/or diastereomers. Furthermore, certain compounds, as described herein may have one or more double bonds that can exist as either the Z or E isomer, unless otherwise indicated.
  • the invention additionally encompasses the compounds as individual isomers (e.g., as either the R or S enantiomer) substantially free of other isomers and alternatively, as mixtures of various isomers, e.g., racemic mixtures of stereoisomers.
  • this invention also encompasses pharmaceutically acceptable derivatives of these compounds and compositions comprising one or more compounds of the invention and one or more pharmaceutically acceptable excipients or additives.
  • this invention provides novel compounds and libraries of compounds useful in the drug discovery process.
  • Compounds and libraries of this invention include those specifically set forth above and described herein, and are illustrated in part by the various classes, subgenera and species disclosed elsewhere herein.
  • inventive compounds and pharmaceutical compositions thereof may be in the form of an individual enantiomer, diastereomer or geometric isomer, or may be in the form of a mixture of stereoisomers.
  • certain of the compounds disclosed herein contain one or more double bonds and these double bonds can be either Z or E, unless otherwise indicated.
  • the compounds of the invention are enantiopure compounds. In certain other embodiments, a mixture of stereoisomers or diastereomers are provided.
  • the present invention provides pharmaceutically acceptable derivatives of the inventive compounds, and methods of treating a subject using these compounds, pharmaceutical compositions thereof, or either of these in combination with one or more additional therapeutic agents.
  • pharmaceutically acceptable derivative denotes any pharmaceutically acceptable salt, ester, or salt of such ester, of such compound, or any other adduct or derivative which, upon administration to a patient, is capable of providing (directly or indirectly) a compound as otherwise described herein, or a metabolite or residue thereof.
  • pro-drugs are a derivative of a compound, usually with significantly reduced pharmacological activity, which contains an additional moiety that is susceptible to removal in vivo yielding the parent molecule as the pharmacologically active species.
  • An example of a pro-drug is an ester which is cleaved in vivo to yield a compound of interest.
  • Pro-drugs of a variety of compounds, and materials and methods for derivatizing the parent compounds to create the pro-drugs are known and may be adapted to the present invention.
  • the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999, the entire contents of which are incorporated herein by reference. Furthermore, it will be appreciated by one of ordinary skill in the art that the synthetic methods, as described herein, utilize a variety of protecting groups.
  • protecting group By the term “protecting group”, has used herein, it is meant that a particular functional moiety, e.g., O, S, or N, is temporarily blocked so that a reaction can be carried out selectively at another reactive site in a multifunctional compound.
  • a protecting group reacts selectively in good yield to give a protected substrate that is stable to the projected reactions; the protecting group must be selectively removed in good yield by readily available, preferably nontoxic reagents that do not attack the other functional groups; the protecting group forms an easily separable derivative (more preferably without the generation of new stereogenic centers); and the protecting group has a minimum of additional functionality to avoid further sites of reaction.
  • oxygen, sulfur, nitrogen and carbon protecting groups may be utilized.
  • oxygen protecting groups include, but are not limited to methyl ethers, substituted methyl ethers (e.g., MOM (methoxymethyl ether), MTM (methylthiomethyl ether), BOM (benzyloxymethyl ether), PMBM (p-methoxybenzyloxymethyl ether), to name a few), substituted ethyl ethers, substituted benzyl ethers, silyl ethers (e.g., TMS (trimethylsilyl ether), TES (triethylsilylether), TIPS (triisopropylsilyl ether), TBDMS (t-butyldimethylsilyl ether), tribenzyl silyl ether, TBDPS (t-butyldiphenyl silyl ether), to name a few), esters (e.g., formate, acetate, benzoate (Bz), trifluor
  • nitrogen protecting groups are utilized. These nitrogen protecting groups include, but are not limited to, carbamates (including methyl, ethyl and substituted ethyl carbamates (e.g., Troc), to name a few) amides, cyclic imide derivatives, N-Alkyl and N-Aryl amines, imine derivatives, and enamine derivatives, to name a few.
  • the phrase "protected thiol" as used herein refers to a thiol that has been reacted with a group or molecule to form a covalent bond that renders it less reactive and which may be deprotected to regenerate a free thiol.
  • the compounds, as described herein, may be substituted with any number of substituents or functional moieties.
  • substituted whether preceded by the term “optionally” or not, and substituents contained in formulas of this invention, refer to the replacement of hydrogen radicals in a given structure with the radical of a specified substituent.
  • the substituent may be either the same or different at every position.
  • substituted is contemplated to include all permissible substituents of organic compounds.
  • the permissible substituents include acyclic and cyclic, branched and unbranched, carbocyclic and heterocyclic, aromatic and non-aromatic substituents of organic compounds.
  • heteroatoms such as nitrogen may have hydrogen substituents and/or any permissible substituents of organic compounds described herein which satisfy the valencies of the heteroatoms.
  • this invention is not intended to be limited in any manner by the permissible substituents of organic compounds.
  • Combinations of substituents and variables envisioned by this invention are preferably those that result in the formation of stable compounds useful in the treatment, for example of caspase-mediated disorders, as described generally above.
  • stable as used herein, preferably refers to compounds which possess stability sufficient to allow manufacture and which maintain the integrity of the compound for a sufficient period of time to be detected and preferably for a sufficient period of time to be useful for the purposes detailed herein.
  • aliphatic includes both saturated and unsaturated, straight chain (i.e., unbranched), branched, cyclic, or polycyclic aliphatic hydrocarbons, which are optionally substituted with one or more functional groups.
  • aliphatic is intended herein to include, but is not limited to, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, and cycloalkynyl moieties.
  • alkyl includes straight, branched and cyclic alkyl groups.
  • alkyl alkenyl
  • alkynyl alkynyl
  • lower alkyl is used to indicate those alkyl groups (cyclic, acyclic, substituted, unsubstituted, branched or unbranched) having 1-6 carbon atoms.
  • the alkyl, alkenyl and alkynyl groups employed in the invention contain 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-6 aliphatic carbon atoms.
  • the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-4 carbon atoms.
  • Illustrative aliphatic groups thus include, but are not limited to, for example, methyl, ethyl, n-propyl, isopropyl, cyclopropyl, -CH 2 -cyclopropyl, allyl, n-butyk sec-butyl, isobutyl, tert-butyl, cyclobutyl, -CH 2 -cyclobutyl, n-pentyl, sec-pentyl, isopentyl, tert-penryl, cyclopentyl, -CH 2 -cyclopentyl-n, hexyl, sec-hexyl, cyclohexyl, -CH 2 -cyclohexyl moieties and the like, which again, may bear one or more substituents.
  • Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, l-methyl-2-buten-l-yl, and the like.
  • Representative alkynyl groups include, but are not limited to, ethynyl, 2-propynyl (propargyl), 1-propynyl and the like.
  • alkoxy or "alkyloxy"
  • thioalkyl refers to an alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom or through a sulfur atom. In certain embodiments, the alkyl group contains 1-20 aliphatic carbon atoms.
  • the alkyl group contains 1-10 aliphatic carbon atoms. In yet other embodiments, the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms.
  • alkoxy include but are not limited to, methoxy, ethoxy, propoxy, isopropoxy, n-butoxy, tert-butoxy, neopentoxy and n-hexoxy.
  • Examples of thioalkyl include, but are not limited to, methylthio, ethylthio, propylthio, isopropylthio, n- butylthio, and the like.
  • alkylamino refers to a group having the structure -NHR'wherein R' is alkyl, as defined herein.
  • dialkylamino refers to a group having the structure — N(R') 2 , wherein R' is alkyl, as defined herein.
  • aminoalkyl refers to a group having the structure NH 2 R'-, wherein R' is alkyl, as defined herein.
  • the alkyl group contains 1-20 aliphatic carbon atoms. In certain other embodiments, the alkyl group contains 1-10 aliphatic carbon atoms.
  • the alkyl, alkenyl, and alkynyl groups employed in the invention contain 1-8 aliphatic carbon atoms. In still other embodiments, the alkyl group contains 1-6 aliphatic carbon atoms. In yet other embodiments, the alkyl group contains 1-4 aliphatic carbon atoms.
  • alkylamino include, but are not limited to, methylamino, ethylamino, iso-propylamino and the like.
  • substituents of the above-described aliphatic (and other) moieties of compounds of the invention include, but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO 2 ; - CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; -CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; -CH 2 SO 2 CH 3 ; -C(O)R ; - CO 2 (R); -CON(R ' ) 2 ; -OC(O)R ; -OCO 2 R ; -OCON(R) 2 ; -N
  • aryl and heteroaryl refer to stable mono- or polycyclic, heterocyclic, polycyclic, and polyheterocyclic unsaturated moieties having preferably 3-14 carbon atoms, each of which may be substituted or unsubstituted.
  • Substituents include, but are not limited to, any of the previously mentioned substitutents, i.e., the substituents recited for aliphatic moieties, or for other moieties as disclosed herein, resulting in the formation of a stable compound.
  • aryl refers to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, indenyl and the like.
  • heteroaryl refers to a cyclic aromatic radical having from five to ten ring atoms of which one ring atom is selected from S, O and N; zero, one or two ring atoms are additional heteroatoms independently selected from S, O and N; and the remaining ring atoms are carbon, the radical being joined to the rest of the molecule via any of the ring atoms, such as, for example, pyridyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, and the like.
  • aryl and heteroaryl groups can be unsubstituted or substituted, wherein substitution includes replacement of one or more of the hydrogen atoms thereon independently with any one or more of the following moieties including, but not limited to: aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; - CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; -CH 2 SO CH 3 ; -C(O)R ; -CO 2 (R); -CON(R) 2
  • cycloalkyl refers specifically to groups having three to seven, preferably three to ten carbon atoms.
  • Suitable cycloalkyls include, but are not limited to cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like, which, as in the case of other aliphatic, heteroaliphatic or hetercyclic moieties, may optionally be substituted with substituents including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; - CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; -CH 2 SO 2 CH 3
  • heteroaliphatic refers to aliphatic moieties which contain one or more oxygen sulfur, nitrogen, phosphorus or silicon atoms, e.g., in place of carbon atoms. Heteroaliphatic moieties may be branched, unbranched, cyclic or acyclic and include saturated and unsaturated heterocycles such as morpholino, pyrrolidinyl, etc.
  • heteroaliphatic moieties are substituted by independent replacement of one or more of the hydrogen atoms thereon with one or more moieties including, but not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; -OH; -NO 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; -CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; - CH 2 SO 2 CH 3 ; -C(O)R ; -C0 2 (R ); -CON(R) 2 ; -OC(O)R ; -OCO R ; -OCON(R) 2 ; -
  • any of the cycloaliphatic or heterocycloaliphatic moieties described above and herein may comprise an aryl or heteroaryl moiety fused thereto. Additional examples of generally applicable substituents are illustrated by the specific embodiments shown in the Examples that are described herein.
  • haloalkyl denotes an alkyl group, as defined above, having one, two, or three halogen atoms attached thereto and is exemplified by such groups as chloromethyl, bromoethyl, trifluoromethyl, and the like.
  • heterocycloalkyl refers to a non- aromatic 5-, 6- or 7- membered ring or a polycyclic group, including, but not limited to a bi- or tr-cyclic group comprising fused six-membered rings having between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, wherein (i) each 5- membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (ii) the nitrogen and sulfur heteroatoms may be optionally be oxidized, (iii) the nitrogen heteroatom may optionally be quatemized, and (iv) any of the above heterocyclic rings may be fused to a substituted or unsubstituted aryl or heteroaryl ring.
  • heterocycles include, but are not limited to, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, and tetrahydrofuryl.
  • a "substituted heterocycloalkyl or heterocycle” group refers to a heterocycloalkyl or heterocycle group, as defined above, substituted by the independent replacement of one or more of the hydrogen atoms thereon with but are not limited to aliphatic; heteroaliphatic; aryl; heteroaryl; alkylaryl; alkylheteroaryl; alkoxy; aryloxy; heteroalkoxy; heteroaryloxy; alkylthio; arylthio; heteroalkylthio; heteroarylthio; F; CI; Br; I; - OH; -N0 2 ; -CN; -CF 3 ; -CH 2 CF 3 ; -CHC1 2 ; -CH 2 OH; -CH 2 CH 2 OH; -CH 2 NH 2 ; -CH 2 SO 2 CH 3 ; - C(O)R ; -CO 2 (R); -CON(
  • ligand candidate refers to a compound that possesses or has been modified to possess a reactive group that is capable of forming a covalent bond with a complimentary or compatible reactive group on a target.
  • the reactive group on either the ligand candidate or the target can be masked with, for example, a protecting group.
  • site of interest refers to any site on a target on which a ligand can bind.
  • a site of interest is any site that is outside of the primary binding site of a protein. For example, if a target is an enzyme, a site of interest is a site that is not the active site. If a target is a receptor, a site of interest is a site that is not the binding site of the receptor's ligand. '
  • target refers to a chemical or biological entity for which the binding of a ligand has an effect on the function of the target.
  • the target can be a molecule, a portion of a molecule, or an aggregate of molecules.
  • the binding of a ligand may be reversible or irreversible.
  • Specific examples of target molecules include polypeptides or proteins (e.g., enzymes, including proteases, e.g.
  • TBMs Target Biological Molecules
  • a "Target Biological Molecule” or “TBM” as used herein refers to a single biological molecule or a plurality of biological molecules capable of forming a biologically relevant complex with one another for which a small molecule agonist or antagonist has an effect on the ruction of the TBM.
  • the TBM is a protein or a portion thereof or that comprises two or more amino acids, and which possesses or is capable of being modified to possess a reactive group that is capable of forming a covalent bond with a compound having a complementary reactive group.
  • TBMs include: enzymes, receptors, transcription factors, ligands for receptors, growth factors, immunoglobulins, nuclear proteins, signal transduction components, glycoproteins, glycolipids, and other macromolecules, such as nucleic acid-protein complexes, chromatin or ribosomes, lipid bilayer-containing structures, such as membranes, or structures derived from membranes, such as vesicles.
  • the target can be obtained in a variety of ways, including isolation and purification from natural source, chemical synthesis, recombinant production and any combination of these and similar methods.
  • Preferred protein targets include: cell surface and soluble receptor proteins, such as lymphocyte cell surface receptors; enzymes; proteases (e.g., aspartyl, cysteine, metallo, and serine); steroid receptors; nuclear proteins; allosteric enzymes; clotting factors; kinases (serine/threonine kinases and tyrosine kinases); phosphatases (serine/threonine, tyrosine, and dual specificity phosphatases, especially PTP-1B, TC-PTP and LAR); thymidylate synthase; bacterial enzymes, fungal enzymes and viral enzymes (especially those associated with HIV, influenza, rhinovirus and RSV); signal transduction molecules; transcription factors; proteins or enzymes associated with DNA and/or RNA synthesis or degradation; immunoglobulins; hormones; and receptors for various cytokines.
  • cell surface and soluble receptor proteins such as lymphocyte cell surface receptors
  • enzymes proteases (e.
  • receptors include for example, erythropoietin (EPO), granulocyte colony stimulating (G-CSF) receptor, granulocyte macrophage colony stimulating (GM-CSF) receptor, thrombopoietin (TPO), interleukins, e.g.
  • EPO erythropoietin
  • G-CSF granulocyte colony stimulating
  • GM-CSF granulocyte macrophage colony stimulating
  • TPO thrombopoietin
  • interleukins e.g.
  • IGF-1 insulinlike growth factor 1
  • EGF epidermal growth factor
  • VEGF vascular endothelial growth factor
  • PLGF placental growth factor
  • TGF- ⁇ and TGF- ⁇ tissue growth factors
  • nerve growth factor nerve growth factor
  • Targets include various neurotrophins and their ligands, other hormones and receptors such as, bone morphogenic factors, follicle stimulating hormone (FSH), and luteinizing hormone (LH), CD40 ligand, apoptosis factor-1 and -2 (AP-1 and AP-2), p53, bax/bcl2, mdm2, caspases (1, 3, 8 and 9), cathepsins, IL-1 /IL-1 receptor, BACE, HIV integrase, PDE IV, Hepatitis C helicase, Hepatitis C protease, rhinovirus protease, tryptase, cPLA (cytosolic Phospholipase A2), CDK4, c-jun kinase, adaptors such as Grb2, GSK-3, AKT, MEKK-1, PAK-1, raf, TRAF's 1- 6, Tie2, ErbB 1 and 2, FGF, PDGF, PARP, CD2, C5a
  • alkyl acids, aryl acids, primary alkyl amines, secondary alkyl amines, secondary aryl amines, aldehydes and ketones can be utilized as described in more detail above and herein.
  • each of these building blocks may be purchased from a commercial source, or may be synthesized to generate a building block of particular interest.
  • building blocks that are purchased from a commercial source may also be further derivatized to generate additional diverstiy (see “1+ nub” chemistry, and the synthesis of "N-side” and "C-side” compounds and libraries as described in the exemplification herein).
  • linkers for use in the invention include, but are not limited to the following linkers shown directly below:
  • the amine linkers are generally employed for building blocks bearing a carboxylate, sulfonylchloride or isocyanate, while carboxylate linkers are generally employed for the derivatization of amines.
  • the length of the linker can be varied as necessary to sample the surface of a given protein, or more generally, of a target of interest.
  • standard coupling conditions are utilized to couple a desired building block and a desired linker as described in more detail herein.
  • these building blocks can be further derivatized to "customize" reagents, as described in more detail herein.
  • the general tethering method relies upon the formation of a covalent bond between the target and a potential ligand.
  • the covalent bond that is formed between the target and the potential ligand allows the facile determination of both binding stoichiometry and binding location.
  • the tethering method is described in U.S. Patent No. 6,335,155, PCT Publication No. WO 00/00823, and Erlanson et al, Proc. Nat. Acad. Sci. USA 97:9367-9372 (2000) which are all incorporated herein by reference and is described briefly below.
  • the compounds and libraries of compounds are useful in the above-described method.
  • a method for ligand discovery comprising: 1) contacting a target that comprises a chemically reactive group at or near a site of interest with a compound or library of compounds as described herein, which compound or library of compounds is capable of forming a covalent bond with a chemically reactive group; 2) forming a covalent bond between the target and the compound thereby forming a target-compound conjugate; and 3) identifying the target compound conjugate.
  • Figure 1 schematically illustrates one embodiment of the tethering method.
  • the target is a protein and the covalent bond is a disulfide bond.
  • a thiol- containing protein is reacted with a plurality of ligand candidates.
  • Ligand candidates are potential ligands that have been modified to include a moiety that is capable of forming a disulfide bond.
  • This moiety can be a thiol group or a masked thiol such as a disulfide of the formula -SSR where R is unsubstituted Ci-Cio aliphatic, substituted - o aliphatic, unsubstituted aryl or substituted aryl.
  • R is selected to enhance the solubility of the potential ligand candidates.
  • Illustrative examples of ligand candidates include those as described in detail above and herein.
  • ligand candidates include, but are not limited to:
  • r is 1 or 2; and t is 0, 1 or 2.
  • tethered compounds as described above may be characterized using X-ray crystallography methods.
  • X-ray crystallography as a characterization method (or other characterization methods)
  • compounds and libraries of special interest include those compounds and
  • Wn represents one of the structures having a substituted thiosulfonate moiety, which moiety, upon exposure to reducing conditions, results in homogeneous compounds: wherein r is 1 or 2; and R ⁇ 2 is an alkyl, heteroalkyl, aryl, heteroaryl, -(alkyl)aryl, (alkyl)heteroaryl, -(heteroalkyl)aryl, or -(heteroalkyl)heteroaryl moiety.
  • R ⁇ is methyl or phenyl.
  • FIG. 1B schematically illustrates the theory behind tethering.
  • a thiol- containing protein is equilibrated with at least one disulfide-containing ligand candidate, equilibrium is established between the modified and unmodified protein.
  • the reaction occurs in the presence of a reducing agent. If the ligand candidate does not have an inherent binding affinity for the target protein, the equilibrium is shifted toward the unmodified protein.
  • TS thymidylate synthase
  • DHFR dihydrofolate reductase
  • dTMP DNA base thymidine 5'-monophosphate
  • Both TS and DHRF are targets for anticancer drug development. Because the TS gene is also found in many viruses, it is also a target for development of anti-parasitic, anti- fungal, and anti-viral agents.
  • TS is an ideal validating target for several reasons. First, numerous high resolution crystal structures of various TS enzymes have been determined so that structural information can be incorporated into compound design. Second, a simple colorimetric assay exists for determining whether a potential ligand binds to TS. This assay depends on the rate of conversion of 5,10-CH ⁇ HUfolate to H 2 folate in the presence of dUMP. A second assay for binding is also spectrophotometric and relies on competition with pyridoxal-5 '-phosphate ("PLP”), which forms a complex with TS with a unique spectral signature. [0088] The TS chosen for the purposes of illustration is the E. coli TS.
  • TS enzymes Like all TS enzymes, it contains a naturally occurring cysteine residue in the active site (Cys 146) that can be used for tethering.
  • the E. coli TS includes four other cysteines but these are not conserved among other TS enzymes and are buried and thus not accessible. However, if one or more of these cysteines were reactive toward disulfides, then mutant versions of these enzymes can be used where these cysteines are mutated to another amino acid such as alanine.
  • R c is unsubstituted -Cio alkyl, substituted C C ⁇ alkyl, unsubstituted aryl, or substituted aryl, and is the variable moiety among this pool of library members.
  • Figure 2A is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates with little or no binding affinity for TS. In the absence of any binding interactions, the equilibrium in the disulfide exchange reaction between TS and an individual ligand candidate is to the unmodified enzyme. This is schematically illustrated by the following equation.
  • the peak that corresponds to the unmodified enzyme is one of two most prominent peaks in the spectrum.
  • the other prominent peak is TS where the thiol of Cys 146 has been modified with cysteamine.
  • TS thiol of Cys 146
  • this species is not formed to a significant extent for any individual library member, the peak is due to the cumulative effect of the equilibrium reactions for each member of the library pool.
  • a thiol-containing reducing agent such as 2-mercaptoethanol
  • the active site cysteine can also be modified with the reducing agent.
  • cysteamine and 2- mercaptoethanol have similar molecular weights, their respective disulfide bonded TS enzymes are not distinguishable under the conditions used in this experiment.
  • the small peaks on the right correspond to discreet library members. Notably, none of these peaks are very prominent.
  • Figure 2A is characteristic of a spectrum where none of the ligand candidates possesses an inherent binding affinity for the target.
  • Figure 2B is the deconvoluted mass spectrum of the reaction of TS with a pool of 10 different ligand candidates where one of the ligand candidates possesses an inherent binding affinity to the enzyme. As can be seen, the most prominent peak is the one that corresponds to TS where the thiol of Cys 146 has been modified with the N-tosyl-£ ) -proline compound. This peak dwarfs all others including those corresponding to the unmodified enzyme and TS where the thiol of Cysl46 has been modified with cysteamine.
  • Figure 2B is an example of a mass spectrum where tethering has captured a moiety that possesses a strong inherent binding affinity for the desired site.
  • FIG. 3 is an illustration of this phenomenon and shows three experiments where TS is reacted with the same library pool containing the selected N-tosyl-D-proline compound in the presence of increasing concentration of the reducing agent, 2-mercaptoethanol.
  • Figure 3A is the deconvoluted mass spectrum when the reaction is performed without 2-mercaptoethanol.
  • the most prominent peak corresponds to TS that has been modified with cysteamine.
  • the peak corresponding to N-tosyl-Z)-proline is nevertheless moderately selected over the other ligand candidates.
  • Figure 3B is the deconvoluted mass spectrum when the reaction is in the presence of 0.2 mM 2- mercaptoethanol.
  • the peak corresponding tosyl-D-proline is the most prominent peak and thus is strongly selected over the other ligand candidates.
  • Figure 3C is the deconvoluted mass spectrum when the reaction is in the presence of 20 mM 2-mercaptoethanol.
  • the most prominent peak under such strongly reducing conditions is the unmodified enzyme. Nevertheless, the peak corresponding to N-tosyl-E>-proline is still selected over that of the other ligand candidates in the library pool.
  • Figure 3 highlights the fact that the degree of cysteine modification in a target protein by a particular ligand candidate that possesses an inherent affinity for the target is, in part, a function of the reducing agent concentration.
  • concentration of the reducing agent used in the tethering screen can be used as a surrogate for binding affinity as well as to set a lower limit of binding affinity the ligand candidate must have to be strongly selected.
  • the tethering method can be used with a single ligand candidate or a plurality of ligand candidates.
  • the tethering method is used to screen a plurality of ligand candidates (e.g., 5, 20, 100, 500, 1000, and even >1000) to maximize throughput and efficiency.
  • a structure-activity relationship can be developed using information from a tethering experiment in much the same way SAR is developed using traditional assays. For example, ligand candidates with R c s on the left hand side of the scheme below were strongly selected against the E. coli TS but those ligand candidates with R c s on the right hand side were not.
  • the phenyl-sulfonamide core and the proline ring are essential.
  • TS appears to accommodate a great deal of flexibility around the phenyl ring where the phenyl ring can be unsubstituted or substituted with a range of groups including methyl, t- butyl, and halogen, its presence is required for selection.
  • the proline ring appears essential because compounds where it was replaced with phenylalanine, phenylglycine or pyrrole were not selected.
  • the tethering experiment is performed in the presence of a known substrate. If the selected ligand candidate possesses an inherent binding affinity for the target, it would be resistant to displacement by the substrate. In contrast, a ligand candidate that lacks an inherent binding affinity or cysteamine would be easily displaced by the substrate.
  • Another illustrative example is traditional enzymatic assays on the tether-free analog. For example, the affinity of the R c portion of the ligand fragment was determined using Michaelis-Mention kinetics. The Kj of the free acid 1 was 1.1 ⁇ 0.25 mM. Notably, the free acid competed with the natural substrate dUMP. Thus, N-tosyl-jD-proline 1 is a weak but competitive inhibitor of TS
  • X-ray crystallography was used to solve the three-dimensional structures of the native enzyme and several complexes to confirm that the information obtained from tethering can be correlated with productive binding to the target.
  • Table 1 details crystallographic data and refinement parameters.
  • One complex was of the free acid of ⁇ -tosyl-D-proline bound to TS (fourth entry in Table 1).
  • Another complex was of the ⁇ -tosyl-D-proline derivative tethered to the active site cysteine (Cys-146) (second entry in Table 1).
  • Yet another complex was of ⁇ -tosyl-D-proine derivative tethered to the C146S/L143C mutant (third entry in Table
  • Noncovalent I2 ⁇ 3 a 131.88 10 - 1.90 202,300 31,422 100 (100) 7.4 (28.2) 19.7 (3.8) 19.2 23.8 0.011 2.49
  • Glu-TP P6 3 a 126.14 c - 66.81 10 - 2.00 143,599 40,497 99.4(96.9) 8.5 (31.9) 13.9(4.0) 19.4 25.1 0.007 2.15
  • Glu-TP-ff-Ala P6 3 a - 126.03 c 66.84 10 - 1.75 142,016 58,487 95.8 (85.2) 4.0 (22.5) 17.1 (4.9) 18.0 21.4 0.007 2.00
  • the I2t3 crystal contains one monomer per asymmetric unit.
  • the P6 3 f orm contains the biologically relevant homodimer. /alues in parentheses are for the highest resolution bin. '" ⁇ » (0 - ⁇ wi
  • N-tosyl-D-proline moiety is very similar in all three cases (RMSD of 0.55 - 1.88 A, compared to 0.11 - 0.56 A for all C ⁇ carbons in the protein).
  • RMSD 0.55 - 1.88 A
  • alkyl- disulfide tethers converge onto this moiety from different cysteine residues supports the notion that the N-tosyl-D-proline moiety, not the tether, is the binding determinant.
  • tethering is a powerful method that can identify ligands that bind to a site of interest in a target.
  • Tethering can be used alone or in combination with other medicinal chemistry methods to identify and optimize a drug candidate.
  • tethering is used to identify a binding determinant (e.g. R c ) and then traditional medicinal chemistry is used to make higher affinity compounds containing the identified binding determinants or variations thereof.
  • tethering is used to both identify a binding determinant and also used to assess whether compounds containing variations of the identified binding determinants bind to the target with higher affinity.
  • tethering can be used as an alternative to traditional binding experiments where either functional assays are not available or are susceptible to artifacts. This approach is schematically illustrated in Figure 4.
  • tethering is used to identify a binding determinant R D .
  • a binding determinant is identified, traditional medicinal chemistry approaches are used to synthesize variants of R D in a modified library.
  • the modified library of ligand candidates would include variants of R D such as isosteres and homologs thereof.
  • the modified library can also include "extended" compounds that include R D or variations thereof as well as other binding determinants that can take advantage of adjacent binding regions.
  • Figure 4 illustrates a selected compound from the modified library wherein the original binding determinant R was modified to R and the selected compound includes a second binding determinant R L .
  • the Kj of compound 2 was determined to be about 55 ⁇ M and the Kj of compound
  • the method comprises: a) identifying a first compound that binds to a target protein; b) identifying a second compound that binds to the target protein; and, c) linking the first compound and second compound through a linker element to form a conjugate molecule that binds to the target protein.
  • the conjugate molecule binds to the target protein with higher binding affinity than either the first compound or second compound alone.
  • the first compound is of the formula R K SSR and the second compound is of the formula R SSR (where R" is as previously described and R ⁇ and R L are each independently C ⁇ -C 20 unsubstituted aliphatic, -C 2 o substituted aliphatic, unsubstituted aryl, or substituted aryl) and the first and second compounds bind to the target protein through a disulfide bond.
  • Figure 5 is a schematic illustration of this method where two separate tethering experiments are used to identify binding determinants R ⁇ and R L that are subsequently linked together to form a conjugate molecule that binds to the target protein.
  • the tethering experiments to identify binding determinants R ⁇ and R L occur simultaneously. In this way, it is assured that the two identified binding determinants bind to the target protein at non-overlapping sites.
  • the first compound is identified using tethering and the second compound is identified through a non-tethering method.
  • the non- tethering method comprised rational drug design and traditional medicinal chemistry.
  • the crystal structure of N-tosyl-D-proline bound to TS revealed that the tosyl group is in roughly the same position and orientation as the benzamide moiety of methylenetetrahydrofolate, the natural cofactor for the TS enzyme. Consequently, the glutamate moiety of methylenetetrahydrofoloate was grafted onto compound 1.
  • Table 2 shows a selected number of these compounds. TABLE 2
  • a variation on the tethering method for use in making and optimizing compounds
  • the method comprises: a) providing a target having a reactive nucleophile at or near a site of interest; and b) contacting the target with an extender thereby forming a target-extender complex wherein the extender comprises a first functionality that reacts with the nucleophile in the target to form a covalent bond and a second functionality that is capable of forming a disulfide bond; c) contacting the target-extender complex with a ligand candidate that is capable of forming a disulfide bond; d) forming a disulfide bond between the target-extender complex and the ligand candidate thereby forming a target-extender-ligand conjugate; and e) identifying the ligand candidate present in the target-extender-ligand conjugate.
  • a reducing agent include but are not limited to: cysteine, cysteamine, dithiothreitol, dithioerythritol, glutathione, 2-mercaptoethanol, 3- mercaptoproprionic acid, a phosphine such as tris-(2-carboxyethyl-phosphine) ("TCEP"), or sodium borohydride.
  • TCEP tris-(2-carboxyethyl-phosphine)
  • the reducing agent is 2-mercaptoethanol.
  • the reducing agent is cysteamine.
  • the reducing agent is glutathione.
  • the reducing agent is cysteine.
  • the target comprises a -SH as the reactive nucleophile and the extender comprises a first functionality that is capable of forming a covalent bond with the reactive nucleophile on the target and a second functionality that is capable of forming a disulfide bond.
  • the reactive nucleophile on the target is a naturally occurring -SH from a cysteine that is part of the naturally occurring protein sequence.
  • the reactive nucleophile on the target is an engineered -SH group where mutagenesis was used to mutate a naturally occurring amino acid to a cysteine.
  • the first and second functionalities of the extender are each independently a -SH or a masked -SH.
  • a masked thiol is a disulfide of the formula -SSR where R is as previously described.
  • the covalent bond formed between the target and the extender is a disulfide bond and thus is a reversible covalent bond.
  • the target is contacted with the extender prior to contacting the target-extender complex with one or more ligand candidates.
  • the target is contacted with a pool comprising the extender and one or more ligand candidates.
  • the first functionality is a group that is capable of forming an irreversible covalent bond with the reactive nucleophile of the target under conditions that do not denature the target and the second functionality is a -SH or a masked -SH.
  • the first functionality is a group capable of undergoing SN2-like addition.
  • extenders include: (i) ⁇ -halo acids such as
  • R is unsubstituted -C 20 aliphatic, substituted C ⁇ -C 20 aliphatic, unsubstituted aryl, and substituted aryl;
  • R' is H, -SR wherein R has been previously defined; and
  • X is a leaving group.
  • the first functionality is a group capable of undergoing SN aryl like addition.
  • suitable groups include 7-halo-2,l,3-benzoxadiazaoles, and ortho/para nitro substituted halobenzenes such as where R' and X are as previously defined.
  • the first functionality is a group capable of undergoing
  • extenders include:
  • R' is as previously defined.
  • Figure 6 illustrates one embodiment of the tethering method using extenders.
  • a target that includes a reactive nucleophile -SH is contacted with an extender comprising a first functionality X that is capable of forming a covalent bond with the reactive nucleophile and a second functionality -SR (where R is the same as R as defined above) that is capable of forming a disulfide bond.
  • a tether-extender complex is formed which is then contacted with a plurality of ligand candidates.
  • the extender provides one binding determinant (circle) and the ligand candidate provides the second binding determinant (square) and the resulting binding determinants are linked together to form a conjugate compound.
  • apoptotic target caspase-3 a member of the cysteine aspartyl protease family.
  • caspase-3 a member of the cysteine aspartyl protease family.
  • Caspases are potential drug targets for a variety of therapeutic indications involving excessive or abnormal levels of programmed cell death such as stroke, traumatic brain injury, spinal cord injury, Alzheimer's disease, Huntington's disease, Parkinson's disease, cardiovascular diseases, liver failure, and sepsis.
  • caspase-3 includes a naturally occurring cysteine residue at the active site and has been well characterized both functionally and crystallographically.
  • a suitable extender for use in the caspase-3 active site was designed using the fact that small aspartyl-based arylacyloxymethyl ketones are known to react irreversibly with the active site cysteine.
  • Two illustrative examples of suitable extenders for use with caspase-3 or other thiol proteases include compounds 13 and 14.
  • compounds 13 and 14 include an aspartic acid moiety as the binding determinant.
  • the carbonyl of the aspartic acid moiety is also part of the first functionality (the arylacyloxymethyl ketone moiety) that forms a covalent bond with the thiol of the active site cysteine.
  • Extenders 13 and 14 also include a second functionality, a masked
  • thioester in the form of a thioester that can be unmasked at the appropriate time.
  • the thioester can be converted into the free thiol by treating the target-extender complex with hydroxylamine.
  • Target-extender complexes 13' and 14' were each used in the tethering method against a library of about 10,000 ligand candidates.
  • An illustrative example of a selected ligand-candidate using target-extender complex 13' is
  • ligand candidate 15 was not selected by target-extender complex 14' and ligand candidate 16 was not selected by target-extender complex 13'. Structure-activity relationships among the selected compounds were also evident. For example, ligand candidate 17,
  • the first structure was of the conjugate that is formed when target-extender complex 13' is contacted with ligand candidate 15.
  • the second structure was of the conjugate that is formed when target-extender complex 14' is contacted with ligand candidate 16.
  • Table 3 summarizes selected crystallographic data for these structures.
  • the aspartic acid moiety of both extenders was superimposable with the aspartyl residue in a known tefrapeptide substrate.
  • the salicylate sulfonamide makes numerous contacts with the protein including four hydrogen bonds.
  • the salicylate moiety occupies the P4 pocket of the enzyme that preferentially recognizes aspartic acid in caspase-3.
  • the sulfone makes some of the same contacts as the salicylate.
  • the target-extender ligand conjugate comprises:
  • the compounds comprise the moiety
  • the compounds are of the structure:
  • Y is CH 2 , S, SO, SO 2
  • R 12 is unsubstituted aryl or substituted aryl.
  • R 12 is a unsubstituted heteroaryl or substituted heteroaryl.
  • An illustrative example of a compound of this class is compound 22 with a K; of 0.33 ⁇ M.
  • the salicylate sulfonamide-containing compounds of the present invention are additionally noteworthy. The identification of salicylate sulfonamide as a suitable P4-binding fragment would not have occurred using traditional medicinal chemistry. Using compound 21 as an example, the salicylate sulfonamide-less version of compound 21 inhibits caspase-3 with a Kj of approximately 28 ⁇ M.
  • compound I has a Kj of 0.051 ⁇ M and the addition of the salicylate sulfonamide moiety to this compound yields compound II that shows about a 300 fold decrease in binding affinity. Because of this dramatic decrease, exploring P4 binding with fripeptides would not have resulted in the identification of salicylate sulfonimide as a suitable P4-binding fragment. Yet, compounds that have this fragment available for binding to P4 are potent inhibitors. Consequently, this example highlights the power of tethering to identify important fragments that may not be found using traditional methods. As shown in the case of caspase-3, these fragments can be linked together to form powerful antagonists or agonists of a target of interest.
  • IL-2 interleukin-2
  • IL-2 is a cytokine with a predominant role in the proliferation of activated T helper lymphocytes. Mitogenic stimuli or interaction of the T cell receptor complex with antigen/MHC complexes on antigen presenting cells causes synthesis and secretion of IL-2 by the activated T cell, followed by clonal expansion of the antigen-specific cells. These effects are known as autocrine effects. In addition, IL-2 can have paracrine effects on the growth and activity of B cells and natural killer (NK) cells. These outcomes are initiated by interaction of IL-2 with its receptor on the T cell surface. Disruption of the IL-2/IL-2R interaction can suppress immune function, which has a number of clinical indications, including graft vs.
  • the compound bound to the target can be readily detected and identified by mass spectroscopy ("MS"). MS detects molecules based on mass- to-charge ratio (m/z) and can resolve molecules based on their sizes (reviewed in Yates, Trends Genet. 16: 5-8 [2000]). The target-compound conjugate can be detected directly in the MS or the target compound conjugate can be fragmented prior to detection.
  • MS mass spectroscopy
  • the compound can be liberated within the mass specfrophotometer and subsequently identified.
  • MS can be used alone or in combination with other means for detection or identifying the compounds covalently bound to the target. Further descriptions of mass spectroscopy techniques include Fitzgerald and Siuzdak, Chemistry & Biology 3: 707-715 [1996]; Chu et al, J. Am. Chem. Soc. 118: 7827-7835 [1996]; Siudzak, Proc. Natl. Acad. Sci. USA 91: 11290-11297 [1994]; Burlingame et al., Anal. Chem.
  • the target-compound conjugate can be identified using other means.
  • various chromatographic techniques such as liquid chromatography, thin layer chromatography and the like for separation of the components of the reaction mixture so as to enhance the ability to identify the covalently bound molecule.
  • Such chromatographic techniques can be employed in combination with mass spectroscopy or separate from mass spectroscopy.
  • a labeled probe fluorescently, radioactively, or otherwise
  • the formation of the new bonds liberates a labeled probe, which can then be monitored.
  • a simple functional assay such as an ELISA or enzymatic assay can also be used to detect binding when binding occurs in an area essential for what the assay measures.
  • Other techniques that may find use for identifying the organic compound bound to the target molecule include, for example, nuclear magnetic resonance (NMR), surface plasmon resonance (e.g., BIACORE), capillary electrophoresis, X-ray crystallography, and the like, all of which will be well known to those skilled in the art.
  • the methods described herein provide powerful techniques for generating drug leads, and allowing the identification of one or more fragments that bind weakly, or with moderate binding affinity, to a target at sites near one another, and the synthesis of diaphores or larger molecules comprising the identified fragments (monophores) covalently linked to each other to produce higher affinity compounds.
  • the monophores, diaphores or similar multimeric compounds including further ligand compounds are valuable tools in rational drug design, which can be further modified and optimized using medicinal chemistry approaches and structure-aided design.
  • the monophores or multiphores identified in accordance with the present invention and the modified drug leads and drugs designed therefrom can be used, for example, to regulate a variety of in vitro and in vivo biological processes which require or depend on the site-specific interaction of two molecules.
  • Molecules which bind to a polynucleotide can be used, for example, to inhibit or prevent gene activation by blocking the access of a factor needed for activation to the target gene, or repress transcription by stabilizing duplex DNA or interfering with the transcriptional machinery.
  • exemplary compounds and libraries of compounds are synthesized by coupling appropriate amine, carboxylic acid, sulfonyl chloride, etc. building blocks with appropriate linkers. Described in more detail below is the synthesis of exemplary linkers and exemplary compounds and libraries of compounds.
  • C. Generation of Building Block Diversity As discussed above, a variety of building blocks can be used to generate the tethering reagents of the invention. For example, a number of commercially available bifunctional amino acids, as shown directly below, are available for use in the present invention. It will be appreciated, however, that the building blocks to be used in the invention are not limited to these particular reagents. Additionally, these commerically available reagents can be subsequently modified to generate "customized" reagents.
  • inventive tethering reagents and libraries of reagents can be prepared using commercially available building blocks, it is also possible to "customize” these building blocks, or alternatively, develop building blocks for the development of further "customized” tethering reagents.
  • constrained amino acid described above can be further modified (for example via C- or N-side modifications as described in more detail herein) to generate additional diversity in the tethering reagents and libraries described herein.
  • Constrained amino acids in certain embodiments are utilized for their precedence in biologically active molecules and theoretical considerations (fewer rotational degrees of freedom, resist hydrophobic collapse, positional and stereochemical isomers can sample different regions of conformational space, etc.).
  • a general schematic for the N- and C-side modification of a constrained amino acid is illustrated directly below: N-side Modification C-side Modification
  • Exemplary constrained amino acid blocks include, but are not limited to:
  • Trifunctional building blocks were also considered advantageous, since the additional point of modification can allow 1) the synthesis of additional regioisomers, 2) combinatorial elaboration/refinement of a monophore hit, and 3) a potential site for recombination with other monophore hits.
  • the latter point may have particular utility with tethering, since hits obtained from different Cys mutants will by definition have their recombination nubs improperly oriented. Few constrained trifunctional building blocks are commercially available.
  • the reagents tr ⁇ r ⁇ -hydroxyproline, and R- and S-piperazine-2-carboxylic acid were available, and this list was supplemented with the unconstrained amino acids D- and L- 2,3-diaminopropionic acid (DAP), Asn, Gin, and Tyr as illustrated in the figure, below.
  • DAP unconstrained amino acids
  • Asn Asn
  • Gin Asn
  • Tyr as illustrated in the figure, below.
  • N-side modifications [00193] Selection of Reagents for "N-side" Modifications. Both the N-terminal and C- terminal sides of a constrained amino acid can be employed for the incorporation of diversity elements. Approximately 200 isocyanates and 100 sulfonylchlorides are available in reasonable quantity commercially, and these sets can be readily examined by simple inspection to select reagents. Just over 250 carboxylic acids were selected. [00194] Exemplary Core Scaffolds. Many constrained amino acid scaffolds were converted into common intermediates for tethering libraries using the scheme illustrated below. Most of these were prepared in 25 mmol quantity, which is sufficient for all 250 planned N-side modifications. [00195] Scaffold synthesis scheme:
  • AU core scaffolds were modified with the N-side diversity inputs to prepare well over 5,000 new monophores. Reactions were performed using EDC/HOBt chemistry in 8:1 DCM/DMF.
  • the vial is allowed to stand, and then the organic (bottom) layer is transferred to a new vial. This solution is then treated with saturated aqueous sodium bicarbonate, and the agitation procedure repeated.
  • a 24-well deep well filter plate is then charged with anhydrous Mg 2 S0 and placed over a rack of 24 tared, bar-coded vials.
  • the final organic layer is dispensed into the filter plate and allowed to drip into the tared vials.
  • a 1 mL DCM wash is added to the filter plate, and the combined filtrates are evaporated to dryness to complete the semi-automated work-up. Boc protection on the cystamine linker is removed with HCl/Dioxane and the vials concentrated to dryness again.
  • C-side modifications consist of the condensation of a highly diverse set of amines with conformationally-constrained core scaffolds bearing free carboxylic acids (see below).
  • the chosen amines comprise 293 inputs that were selected based upon the diversity of functionality that they display.
  • Exemplary Amine Reacations Many of the amines we wished to condense with the above scaffolds contain free hydroxyls, carboxylates, and other functionality that can afford undesired side-products if the amine were simply coupled to a core scaffold using a conventional activating agent. Alternatively, a preformed active ester can often react preferentially with the desired amine and thus minimize side-product formation. Pentafluorophenyl (pFp) esters were first tried since they are often isolated as crystalline solids yet are quite reactive. In model reactions, a representative -OpFp ester was used to acylate a cross-section of amines. Although, products were found, many reactions were incomplete (even after 24 h).
  • chemistries are chosen that are flexible such that simple variations can afford more than one class of building block.
  • Carboxylic acids are common synthons for the synthesis of heterocycles, and simple derivatives of this functional group can be combined with an elecfrophile to create a heterocycle. This is shown schematically, below:
  • Piperazines are the most common motif in the CMC and MDDR, and several N-side Nub+1 libraries have already been prepared from piperazine scaffolds. Shown below is a common intermediate that can be used in the preparation of three piperazine motifs (and their regioisomers), including forms which will ultimately display a basic amine (Boc- protected), a tertiary amine (N-methyl) and an amide (N-acetyl). These three motifs represent fragments of the most common forms of derivatization for this core scaffold. Each of these can be made from the indicated Boc/Fmoc intermediate. After much experimentation, we have devised an efficient two step procedure for the preparation of this intermediate, and over 50 g are currently in-house. Each piperazine motif will be systematically prepared and derivatized using the "Go To" amine set.
  • Oxazoles are also a common motif. A variety of oxazoles were prepared from conformationally constrained amino acids and serine using the route shown below:
  • Example 1 Library 000004 consists of 484 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
  • Example 2 Library 000005 consists of 453 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally-constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
  • R' is defined as for R 5 and R 6 , as described generally herein.
  • Example 3 Library 000006 consists of 453 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of four conformationally-consfrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
  • Example 4 Library 000007 consists of 681 peptidomimetic compounds connected to the cystamine-derived tethering linker. This library consists of six conformationally-constrained amino acid "scaffolds" that were acylated with 121 different carboxylic acids. General formula for the library is as follows:
  • R' is defined as for R 5 and R , as described generally herein.
  • Example 5 Library 000014 was prepared from four conformationally- constrained amino acid "scaffolds" that were used to acylated 293 diverse primary and secondary amines (1172 reactions). After eliminating compounds that failed QC, 690 compounds were released.
  • General formula for the library is as follows:
  • Example 6 Library 000017 was prepared from 10 conformationally-consfrained amino acid "scaffolds" that were used to acylate 220 diverse primary and secondary amines (approx. 2200 reactions). After eliminating compounds that failed QC, 833 compounds were released.
  • General formula for the library is as follows: Scaffolds Boc*
  • Example 7 Library 000018 was prepared from 9 conformationally-constrained amino acid "scaffolds" that were used to acylate 220 diverse primary and secondary amines (approx. 2000 reactions). After eliminating compounds that failed QC, 811 compounds were released.
  • General formula for the library is as follows:
  • Example 8 Library 000016 was prepared from five thiazole core scaffolds, that were used to acylated 220 diverse primary and secondary amines (1100 reactions). 750 of these passed QC and were added to the screening collection. ids,
  • MS mass spectroscopy
  • a mass spectrometer first converts molecules into gas-phase ions, then individual ions are separated on the basis of m/z ratios and are finally detected.
  • a mass analyzer which is an integral part of a mass spectrometer, uses a physical property (e.g. electric or magnetic fields, or time-of-flight [TOF]) to separate ions of a particular m/z value that then strikes the ion detector.
  • a physical property e.g. electric or magnetic fields, or time-of-flight [TOF]
  • Mass spectrometers are capable of generating data quickly and thus have a great potential for high-throughput analysis.
  • MS offers a very versatile tool that can be used for drug discovery.
  • Mass spectroscopy may be employed either alone or in combination with other means for detection or identifying the organic compound ligand bound to the target.
  • Techniques employing mass spectroscopy are well known in the art and have been employed for a variety of applications (see, e.g., Fitzgerald and Siuzdak, Chemistry & Biology 3: 707- 715 [1996]; Chu et al, J. Am. Chem. Soc. 118: 7827-7835 [1996]; Siudzak, Proc. Natl. Acad. Sci.
  • NMR nuclear magnetic resonance
  • capillary electrophoresis capillary electrophoresis
  • X-ray crystallography X-ray crystallography

Abstract

L'invention porte sur des composés et bibliothèques de composés de formule (I) dans laquelle: L et n sont tels que définis dans les revendications, et A est -S(CH2)pRA1 ou -S(O)¿2R?A2, où p, R?A1 et RA2¿ sont tels que définis dans les revendications. Les bibliothèques de composés de formule (I) servent dans des procédés de découverte de médicaments.
EP02746365A 2001-08-07 2002-05-10 Ligands de bisulfure et de thiosulfonate, et bibliotheques les comprenant Withdrawn EP1421063A1 (fr)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US31072501P 2001-08-07 2001-08-07
US310725P 2001-08-07
US990421 2001-11-21
US09/990,421 US6919178B2 (en) 2000-11-21 2001-11-21 Extended tethering approach for rapid identification of ligands
US10/121,216 US6998233B2 (en) 1998-06-26 2002-04-10 Methods for ligand discovery
US121216 2002-04-10
PCT/US2002/014778 WO2003014072A1 (fr) 2001-08-07 2002-05-10 Ligands de bisulfure et de thiosulfonate, et bibliotheques les comprenant

Publications (1)

Publication Number Publication Date
EP1421063A1 true EP1421063A1 (fr) 2004-05-26

Family

ID=27382591

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02746365A Withdrawn EP1421063A1 (fr) 2001-08-07 2002-05-10 Ligands de bisulfure et de thiosulfonate, et bibliotheques les comprenant

Country Status (7)

Country Link
EP (1) EP1421063A1 (fr)
JP (1) JP2004537594A (fr)
CA (1) CA2457814A1 (fr)
IL (1) IL159983A0 (fr)
MX (1) MXPA04001074A (fr)
NZ (1) NZ530811A (fr)
WO (1) WO2003014072A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7214487B2 (en) 1998-06-26 2007-05-08 Sunesis Pharmaceuticals, Inc. Methods for identifying compounds that modulate enzymatic activities by employing covalently bonded target-extender complexes with ligand candidates
US7202033B2 (en) 2002-03-21 2007-04-10 Sunesis Pharmaceuticals, Inc. Identification of kinase inhibitors
CA2577490A1 (fr) * 2004-08-26 2006-03-16 Nicholas Piramal India Limited Promedicaments contenant de nouveaux lieurs bio-clivables
US7544756B2 (en) * 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7544754B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups
US7544755B2 (en) 2005-09-30 2009-06-09 3M Innovative Properties Company Crosslinked polymers with amine binding groups

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU509899B2 (en) * 1976-02-13 1980-05-29 E.R. Squibb & Sons, Inc. Proline derivatives and related compounds
US4614712A (en) * 1983-02-25 1986-09-30 The Upjohn Company Immunoassays with luciferase labeled ligands or receptors
JPH08201958A (ja) * 1995-01-24 1996-08-09 Konica Corp ハロゲン化銀写真感光材料及び画像形成方法
WO1998052619A2 (fr) * 1997-05-22 1998-11-26 Merck Patent Gmbh Implants recouverts de peptides et procede permettant de les preparer
US6344330B1 (en) * 1998-03-27 2002-02-05 The Regents Of The University Of California Pharmacophore recombination for the identification of small molecule drug lead compounds
US6335155B1 (en) * 1998-06-26 2002-01-01 Sunesis Pharmaceuticals, Inc. Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
EP1337853B1 (fr) * 2000-11-21 2009-01-07 Sunesis Pharmaceuticals, Inc. Methode de fixation etendue pour l'identification rapide de ligands

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO03014072A1 *

Also Published As

Publication number Publication date
MXPA04001074A (es) 2004-07-08
IL159983A0 (en) 2004-06-20
JP2004537594A (ja) 2004-12-16
WO2003014072A1 (fr) 2003-02-20
NZ530811A (en) 2005-07-29
CA2457814A1 (fr) 2003-02-20

Similar Documents

Publication Publication Date Title
US20120077711A1 (en) Novel Ligands and Libraries of Ligands
JP7169327B2 (ja) イミド系タンパク質分解モジュレーター及び関連する使用方法
EP1789416B1 (fr) Dérivés amidés de 3-phényl dihydropyrimido[4,5-d]pyrimidinon, leur préparation et utilisation comme medicaments
CA2464094C (fr) Procedes de decouverte de ligands
US6998233B2 (en) Methods for ligand discovery
JP3836791B2 (ja) リガンドの迅速な同定のための拡張されたテザー化アプローチ
CN117736134A (zh) 通过e3泛素连接酶增强靶蛋白质及其他多肽降解的化合物和方法
JP2008509964A (ja) ７−アミノ−３−フェニル−ジヒドロピリミド［４，５−ｄ］ピリミジノンのアミド誘導体、これらの製造、及びプロテインキナーゼ阻害剤としての使用
CN111606970B (zh) 一种1，5-二氮杂双环[5,3,0]十烷酮氨基酸衍生物及其制备方法和应用
JP2019527672A (ja) 多様な大環状化合物のライブラリならびにその製造方法および使用方法
JP2019501188A (ja) ヘテロアリール含有大環状化合物のライブラリならびにその製造方法および使用方法
EP1421063A1 (fr) Ligands de bisulfure et de thiosulfonate, et bibliotheques les comprenant
CA2719579A1 (fr) Procedes d'evolution de chimiotype
AU2002316090A1 (en) Disulfide and thiosulfonate ligands and libraries comprising these ligands
Boudjabi et al. Sulfahydantoins as Tripeptide Constraints: Synthesis and Structure of Chiral Substituted 3‐Oxo‐1, 2, 5‐thiadiazolidine 1, 1‐Dioxides
Marciniak et al. Development of novel PEX5-PEX14 protein-protein interaction (PPI) inhibitors based on an oxopiperazine template
ZA200400745B (en) Disulfide and thiosulfonate ligands and libraries comprising these ligands.
Abdildinova et al. Traceless solid-phase synthesis and β-turn propensity of 1, 3-thiazole-based peptidomimetics

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20040206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE TR

AX Request for extension of the european patent

Extension state: AL LT LV MK RO SI

17Q First examination report despatched

Effective date: 20061127

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070611